OpenLB
Open Library of Bioscience

Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-susceptible Tuberculosis.

Abstract

No abstract text available.

References

1. N Engl J Med. 2021 May 6;384(18):1705-1718 [PMID: 33951360]
2. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0239821 [PMID: 35315690]
3. Am J Respir Crit Care Med. 2023 Apr 1;207(7):929-935 [PMID: 36455068]
4. Clin Infect Dis. 2016 Oct 1;63(7):e147-e195 [PMID: 27516382]
5. N Engl J Med. 2020 Mar 5;382(10):959-960 [PMID: 32130819]
6. Int J Tuberc Lung Dis. 2021 Apr 1;25(4):305-314 [PMID: 33762075]
7. Antimicrob Agents Chemother. 2010 Aug;54(8):3402-7 [PMID: 20498324]
8. N Engl J Med. 2020 Mar 5;382(10):893-902 [PMID: 32130813]
9. Antimicrob Agents Chemother. 2021 Jan 20;65(2): [PMID: 33229425]
10. MMWR Morb Mortal Wkly Rep. 2022 Feb 25;71(8):285-289 [PMID: 35202353]
11. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005159 [PMID: 17943842]
12. N Engl J Med. 2022 Sep 1;387(9):810-823 [PMID: 36053506]
13. Antimicrob Agents Chemother. 2008 Oct;52(10):3664-8 [PMID: 18694943]

Grants

1. K08 AI141740/NIAID NIH HHS
2. R25 AI147375/NIAID NIH HHS
3. UM1 AI068634/NIAID NIH HHS

MeSH Term

Chemicals